Methamphetamine toxicity and its implications during HIV-1 infection.

Area of Science:

• Neuroscience
• Infectious Diseases
• Toxicology

Background:

• Methamphetamine (MA) abuse has significantly increased, particularly among men who have sex with men (MSM), a population at high risk for HIV-1 infection.
• MA abuse and HIV-1 infection share overlapping risk factors and can synergistically impact the central nervous system (CNS).
• Understanding the dual impact of MA and HIV-1 on the CNS and periphery is crucial for public health interventions.

Purpose of the Study:

• To review the neurotoxic effects of methamphetamine (MA) on the central nervous system (CNS) and periphery.
• To explore the interaction between MA abuse and HIV-1 infection, focusing on CNS and peripheral complications.
• To highlight how MA may exacerbate HIV-1-associated neurodegeneration and affect viral load.

Main Methods:

• Review of existing scientific literature on methamphetamine toxicity and HIV-1 infection.
• Analysis of studies using animal models (e.g., SIV-infected macaques, transgenic models) and cell cultures.
• Examination of research on MA's effects on CNS, blood-brain barrier (BBB), and peripheral HIV-1 co-receptor expression.

Main Results:

• MA induces CNS toxicity via oxidative stress, dopaminergic dysregulation, hyperthermia, apoptosis, and neuroinflammation.
• MA exacerbates HIV-1-related neurodegeneration, potentially by targeting frontostriatal regions and increasing CNS viral load.
• MA negatively impacts the blood-brain barrier (BBB) integrity, increasing susceptibility to CNS HIV-1 infection and affecting peripheral HIV-1 expression.

Conclusions:

• Methamphetamine (MA) significantly contributes to CNS damage in HIV-1-infected individuals, particularly among MSM.
• MA's neurotoxic effects, including BBB disruption and neuroinflammation, worsen HIV-1 neuropathogenesis.
• Further research into MA's peripheral effects on HIV-1 infection is warranted to develop comprehensive treatment strategies.